Trial Profile
A phase II trial of oxaliplatin, cytosine arabinoside [cytarabine], dexamethasone with rituxan [rituximab] (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cytarabine; Dexamethasone; Oxaliplatin; Pegfilgrastim
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- 01 Oct 2017 Results published in the American Journal of Hematology
- 30 Oct 2015 Status changed from suspended to completed.
- 04 Aug 2008 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.